Media coverage about Kitov Pharma (NASDAQ:KTOV) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kitov Pharma earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.4215778809455 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Separately, ValuEngine lowered Kitov Pharma from a “hold” rating to a “sell” rating in a report on Thursday, March 1st.
Kitov Pharma stock traded up $0.16 during midday trading on Thursday, hitting $2.59. 163,407 shares of the company were exchanged, compared to its average volume of 114,835. The firm has a market cap of $26.90, a price-to-earnings ratio of -1.99 and a beta of 2.83. Kitov Pharma has a fifty-two week low of $1.27 and a fifty-two week high of $3.44.
Kitov Pharma Company Profile
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Receive News & Ratings for Kitov Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharma and related companies with MarketBeat.com's FREE daily email newsletter.